Intravenous Glial Growth Factor 2 (GGF2) Isoform of Neuregulin-1β Improves Left Ventricular Function, Gene and Protein Expression in Rats after Myocardial Infarction

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Hill, Michael F ^a   Patel, Amish V ^a   Murphy, Abigail ^a   Smith, Holly M ^a   Galindo, Cristi L ^a   Pentassuglia, Laura ^a   Peng, Xuyang ^a   Lenneman, Carrie G ^a,c   Odiete, Oghenerukevwe ^a   Friedman, David B ^b   Kronenberg, Marvin W ^a   Zheng, Siyuen ^a   Zhao, Zhongming ^a   Song, Yanna ^a   Harrell, Frank E ^a   Srinivas, Maya ^c   Ganguly, Anindita ^c   Iaci, Jennifer ^c   Parry, Tom J ^c   Caggiano, Anthony O ^c   Sawyer, Douglas B ^a   more..

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ACORDA THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR AGENT; ELECTRON TRANSFER FLAVOPROTEIN BETA POLYPEPTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GLIAL GROWTH FACTOR 2; GLUTATHIONE PEROXIDASE 3; GLYCOGEN PHOSPHORYLASE; ISOPROTEIN; MESSENGER RNA; MUSCLE PROTEIN; NEU DIFFERENTIATION FACTOR; NEUREGULIN 1BETA; PHOSPHOGLYCERATE MUTASE 2; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR; PROCOLLAGEN TYPE VI ALPHA 3; PROTEIN NDUFS1; TROPONIN 1 TYPE 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG SENSITIVITY; ECHOCARDIOGRAPHY; ELECTRON TRANSFER FLAVOPROTEIN BETA POLYPEPTIDE GENE; ENERGY YIELD; GENE; GENE EXPRESSION; GLUTATHIONE PEROXIDASE 3 GENE; GLYCOGEN PHOSPHORYLASE GENE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; LOW DRUG DOSE; MALE; METABOLIC REGULATION; MICROARRAY ANALYSIS; NDUFS1 GENE; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PHOSPHOGLYCERATE MUTASE 2 GENE; POLYMERASE I AND TRANSCRIPT RELEASE FACTOR GENE; PROCOLLAGEN TYPE VI ALPHA 3 GENE; PROTEIN EXPRESSION; PROTEIN METABOLISM; PROTEOMICS; QUANTITATIVE ANALYSIS; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT DURATION; TROPONIN 1 TYPE 3 GENE;

EID: 84874289558     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055741     Document Type: Article

References (33)

1. Udelson JE, Konstam MA, (2002) Relation between left ventricular remodeling and clinical outcomes in heart failure patients with left ventricular systolic dysfunction. J Card Fail 8: S465-471.
2. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, et al. (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. J Biol Chem 273: 10261-10269.
3. Kuramochi Y, Cote GM, Guo X, Lebrasseur NK, Cui L, et al. (2004) Cardiac endothelial cells regulate reactive oxygen species-induced cardiomyocyte apoptosis through neuregulin-1beta/erbB4 signaling. J Biol Chem 279: 51141-51147.
4. Liu X, Gu X, Li Z, Li X, Li H, et al. (2006) Neuregulin-1/erbB-activation improves cardiac function and survival in models of ischemic, dilated, and viral cardiomyopathy. J Am Coll Cardiol 48: 1438-1447.
5. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, et al. (2011) Parenteral administration of recombinant human neuregulin-1 to patients with stable chronic heart failure produces favourable acute and chronic haemodynamic responses. Eur J Heart Fail 13: 83-92.
6. Gao R, Zhang J, Cheng L, Wu X, Dong W, et al. (2010) A Phase II, randomized, double-blind, multicenter, based on standard therapy, placebo-controlled study of the efficacy and safety of recombinant human neuregulin-1 in patients with chronic heart failure. J Am Coll Cardiol 55: 1907-1914.
7. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM, (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551-1554.
8. Kuramochi Y, Guo X, Sawyer DB, (2006) Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes. J Mol Cell Cardiol 41: 228-235.
9. Grazette LP, Boecker W, Matsui T, Semigran M, Force TL, et al. (2004) Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy. J Am Coll Cardiol 44: 2231-2238.
10. Pentassuglia L, Graf M, Lane H, Kuramochi Y, Cote G, et al. (2009) Inhibition of ErbB2 by receptor tyrosine kinase inhibitors causes myofibrillar structural damage without cell death in adult rat cardiomyocytes. Exp Cell Res 315: 1302-1312.
11. Peng X, Guo X, Borkan SC, Bharti A, Kuramochi Y, et al. (2005) Heat shock protein 90 stabilization of ErbB2 expression is disrupted by ATP depletion in myocytes. J Biol Chem 280: 13148-13152.
12. Miller TA, Icli B, Cote GM, Lebrasseur NK, Borkan SC, et al. (2009) Palmitate alters neuregulin signaling and biology in cardiac myocytes. Biochem Biophys Res Commun 379: 32-37.
13. Marchionni MA, Goodearl AD, Chen MS, Bermingham-McDonogh O, Kirk C, et al. (1993) Glial growth factors are alternatively spliced erbB2 ligands expressed in the nervous system [see comments]. 362: 312-318.
14. Zhao YY, Sawyer DR, Baliga RR, Opel DJ, Han X, et al. (1998) Neuregulins promote survival and growth of cardiac myocytes. Persistence of ErbB2 and ErbB4 expression in neonatal and adult ventricular myocytes. JBiolChem 273: 10261-10269.
15. Ganguly A, iaci JF, Srinivas M, Vecchione AV, Hackett CS, et al. (2008) Neuregulin Treatment of Heart Failure in Rat. Circ Res 103: Abstract e51.
16. Miller TA, Lebrasseur NK, Cote GM, Trucillo MP, Pimentel DR, et al. (2005) Oleate prevents palmitate-induced cytotoxic stress in cardiac myocytes. Biochem Biophys Res Commun 336: 309-315.
17. Bolstad BM, Irizarry RA, Astrand M, Speed TP, (2003) A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 19: 185-193.
18. Parkinson H, Sarkans U, Kolesnikov N, Abeygunawardena N, Burdett T, et al. (2011) ArrayExpress update - an archive of microarray and high-throughput sequencing-based functional genomics experiments. Nucleic Acids Res 39: D1002-1004.
19. Colak D, Kaya N, Al-Zahrani J, Al Bakheet A, Muiya P, et al. (2009) Left ventricular global transcriptional profiling in human end-stage dilated cardiomyopathy. Genomics 94: 20-31.
20. Cardiogenomics PGA HMS Genomics of Cardiovascular Development, Adaptation, and Remodeling. NHLBI Program for Genomic Applications: Available: http://www.cardiogenomics.org.
21. Hannenhalli S, Putt ME, Gilmore JM, Wang J, Parmacek MS, et al. (2006) Transcriptional genomics associates FOX transcription factors with human heart failure. Circulation 114: 1269-1276.
22. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
23. Wessel D, Flugge UI, (1984) A method for the quantitative recovery of protein in dilute solution in the presence of detergents and lipids. Anal Biochem 138: 141-143.
24. Friedman DB, (2007) Quantitative proteomics for two-dimensional gels using difference gel electrophoresis. Methods Mol Biol 367: 219-239.
25. Friedman DB, Hill S, Keller JW, Merchant NB, Levy SE, et al. (2004) Proteome analysis of human colon cancer by two-dimensional difference gel electrophoresis and mass spectrometry. Proteomics 4: 793-811.
26. Alban A, David SO, Bjorkesten L, Andersson C, Sloge E, et al. (2003) A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 3: 36-44.
27. Morgan EE, Rennison JH, Young ME, McElfresh TA, Kung TA, et al. (2006) Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure. Am J Physiol Heart Circ Physiol 290: H1899-1904.
28. Rennison JH, McElfresh TA, Okere IC, Vazquez EJ, Patel HV, et al. (2007) High-fat diet postinfarction enhances mitochondrial function and does not exacerbate left ventricular dysfunction. Am J Physiol Heart Circ Physiol 292: H1498-1506.
29. Rohrbach S, Yan X, Weinberg EO, Hasan F, Bartunek J, et al. (1999) Neuregulin in cardiac hypertrophy in rats with aortic stenosis. Differential expression of erbB2 and erbB4 receptors. Circulation 100: 407-412.
30. Sawyer DB, Caggiano A, (2011) Neuregulin-1beta for the treatment of systolic heart failure. J Mol Cell Cardiol 51: 501-505.
31. Guo YF, Zhang XX, Liu Y, Duan HY, Jie BZ, et al. (2012) Neuregulin-1 attenuates mitochondrial dysfunction in a rat model of heart failure. Chin Med J (Engl) 125: 807-814.
32. Trivedi CM, Cappola TP, Margulies KB, Epstein JA, (2011) Homeodomain only protein x is down-regulated in human heart failure. J Mol Cell Cardiol 50: 1056-1058.
33. Bersell K, Arab S, Haring B, Kuhn B, (2009) Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138: 257-270.